Status:
UNKNOWN
VOC in Breath Samples for the Diagnosis of IPA
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Invasive Pulmonary Aspergillosis
Breath Samples
Eligibility:
All Genders
18-18 years
Brief Summary
The diagnosis of invasive pulmonary aspergillosis (IPA) bears grave implications for the prognosis and treatment plan of the immunosuppressed patient. Thus far, such diagnosis in the immunosuppressed ...
Detailed Description
BACKGROUND The diagnosis of invasive pulmonary aspergillosis (IPA) bears grave implications for the prognosis and treatment plan of the immunosuppressed patient. The omnipresence of Aspergillus spp in...
Eligibility Criteria
Inclusion
- New diagnosis of acute myeloid leukemia AND/OR planned hematopoietic stem cells transplantation (HCT)
- Chest CT performed within 30 days from sampling
- 18 years of age or older
- The ability to provide tidal breath samples totalling 10L directly into a Tedlar bag
Exclusion
- Any condition impairing the patient's ability to provide informed consent
Key Trial Info
Start Date :
March 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05982912
Start Date
March 3 2022
End Date
December 1 2025
Last Update
August 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Healthcare Campus
Haifa, Israel, 9619002